Rhythm Pharmaceuticals (RYTM) Enterprise Value (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) has disclosed Enterprise Value for 10 consecutive years, with -$416.7 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value fell 39.44% to -$416.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$416.7 million, a 39.44% decrease, with the full-year FY2024 number at -$321.0 million, down 16.24% from a year prior.
- Enterprise Value was -$416.7 million for Q3 2025 at Rhythm Pharmaceuticals, down from -$155.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$53.9 million in Q1 2024 to a low of -$416.7 million in Q3 2025.
- A 5-year average of -$214.9 million and a median of -$253.9 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 81.35% in 2023, then crashed 484.46% in 2025.
- Rhythm Pharmaceuticals' Enterprise Value stood at -$295.2 million in 2021, then fell by 13.02% to -$333.6 million in 2022, then grew by 17.22% to -$276.2 million in 2023, then dropped by 16.24% to -$321.0 million in 2024, then decreased by 29.81% to -$416.7 million in 2025.
- Per Business Quant, the three most recent readings for RYTM's Enterprise Value are -$416.7 million (Q3 2025), -$155.4 million (Q2 2025), and -$315.0 million (Q1 2025).